The impact of epiretinal membrane on neovascular age-related macular degeneration treatment: A spectral-domain optical coherence tomography study
Autor: | Konstantinos Ananikas, George Theodossiadis, Eleni Dimitriou, Irini Chatziralli, Panagiotis Theodossiadis, Panagiotis Stavrakas |
---|---|
Rok vydání: | 2017 |
Předmět: |
Male
medicine.medical_specialty genetic structures Fundus Oculi Visual Acuity Angiogenesis Inhibitors Spectral domain 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Optical coherence tomography Ranibizumab Ophthalmology Age related medicine Humans In patient Prospective Studies 030212 general & internal medicine Fluorescein Angiography Prospective cohort study Aged medicine.diagnostic_test business.industry Epiretinal Membrane Retinal General Medicine Macular degeneration medicine.disease Fluorescein angiography eye diseases Treatment Outcome chemistry Intravitreal Injections Wet Macular Degeneration 030221 ophthalmology & optometry Female sense organs Epiretinal membrane business Tomography Optical Coherence medicine.drug |
Zdroj: | Acta Ophthalmologica. 95 |
ISSN: | 1755-375X |
DOI: | 10.1111/j.1755-3768.2017.0f046 |
Popis: | The purpose of this prospective study was to evaluate the impact of epiretinal membrane (ERM) on anatomical and functional results in patients with wet age-related macular degeneration (AMD) treated with intravitreal anti-vascular endothelial growth (anti-VEGF) injections.Participants in the study were 48 patients with either wet AMD alone (AMD group, n = 27) or AMD and ERM (AMD/ERM group, n = 21). All patients received intravitreal anti-VEGF injections (three monthly injections and PRN thereafter) and were followed up for at least 12 months. All participants had best-corrected visual acuity (BCVA) measurement and spectral domain-optical coherence tomography (SD-OCT) at each visit, while fluorescein angiography was performed at baseline and then at the discretion of the physician.There was a statistically significant improvement in BCVA at month 12 compared to baseline in each group (p 0.001 for both groups), while the two groups did not differ significantly regarding BCVA at the end of the follow-up (p = 0.056). Additionally, there was a statistically significant reduction in CRT in both groups at month 12 (p 0.001 for AMD group and p = 0.004 for AMD/ERM group) with no statistically significant difference between the groups (p = 0.183). Patients in the AMD group had a lower percentage of subretinal fluid (25.9%) than patients in the AMD/ERM group (52.4%) at the end of the follow-up, while ellipsoid zone disruption was found to be more profound in the AMD/ERM group (38.1%) than in the AMD group (18.5%). Patients in the AMD/ERM group needed more injections (7.1 ± 2.0 injections) than patients in the AMD group (4.8 ± 1.7 injections).Patients in the AMD/ERM group had a higher percentage of subretinal and intraretinal fluid and ellipsoid zone interruption during the follow-up period. Anti-VEGF treatment appeared to have a beneficial effect in both groups, although the AMD/ERM group needed more injections compared to the AMD group. |
Databáze: | OpenAIRE |
Externí odkaz: |